Cargando…
A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer
Epithelial-mesenchymal transition (EMT) is involved in the characteristics of malignancy, such as invasion, metastasis, and chemoresistance. In biliary tract cancer (BTC), EMT is induced by transforming growth factor-beta 1 (TGF-β1). The EMT is reversible; therefore, it is conceivable that it could...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699768/ https://www.ncbi.nlm.nih.gov/pubmed/26726879 http://dx.doi.org/10.1371/journal.pone.0145985 |
_version_ | 1782408227421421568 |
---|---|
author | Sakamoto, Takuya Kobayashi, Shogo Yamada, Daisaku Nagano, Hiroaki Tomokuni, Akira Tomimaru, Yoshito Noda, Takehiro Gotoh, Kunihito Asaoka, Tadafumi Wada, Hiroshi Kawamoto, Koichi Marubashi, Shigeru Eguchi, Hidetoshi Doki, Yuichiro Mori, Masaki |
author_facet | Sakamoto, Takuya Kobayashi, Shogo Yamada, Daisaku Nagano, Hiroaki Tomokuni, Akira Tomimaru, Yoshito Noda, Takehiro Gotoh, Kunihito Asaoka, Tadafumi Wada, Hiroshi Kawamoto, Koichi Marubashi, Shigeru Eguchi, Hidetoshi Doki, Yuichiro Mori, Masaki |
author_sort | Sakamoto, Takuya |
collection | PubMed |
description | Epithelial-mesenchymal transition (EMT) is involved in the characteristics of malignancy, such as invasion, metastasis, and chemoresistance. In biliary tract cancer (BTC), EMT is induced by transforming growth factor-beta 1 (TGF-β1). The EMT is reversible; therefore, it is conceivable that it could be related to some epigenetic changes. We focused on histone deacetylase (HDAC) inhibitors as regulators of TGF-β1 signaling, and investigated their effect on EMT and chemoresistance. We employed four BTC cell lines (MzChA-1, gemcitabine-resistant MzChA-1, TFK-1, and gemcitabine-resistant TFK-1) and used vorinostat as the HDAC inhibitor. The relative mRNA expression of an epithelial marker (CDH1) and mesenchymal markers (CDH2, vimentin, SNAI1) were measured by qRT-PCR to evaluate factors associated with EMT. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed to evaluate the chemoresistance of each cell line. In addition, NOD/SCID mice were used to evaluate the effect of vorinostat in vivo. In the parent MzChA-1 and TFK-1 cell lines, TGF-β1 induced EMT and chemoresistance; while vorinostat inhibited the EMT and chemoresistance induced by TGF-β1. In gemcitabine-resistant cell lines that highly expressed TGF-β1, vorinostat inhibited EMT and attenuated chemoresistance. We showed that vorinostat inhibits nuclear translocation of SMAD4 which is a signaling factor of TGF-β1, and this is one of the mechanisms by which vorinostat regulates EMT. We also showed that vorinostat attenuates the binding affinity of SMAD4 to the CDH1-related transcription factors SNAI1, SNAI2, ZEB1, ZEB2, and TWIST. Furthermore, combination therapy with vorinostat and gemcitabine improved survival time in the mice xenografted with gemcitabine resistant MzChA-1 cells. In conclusion, vorinostat regulated TGF-β1-induced EMT and chemoresistance through inhibition of SMAD4 nuclear translocation. |
format | Online Article Text |
id | pubmed-4699768 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-46997682016-01-15 A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer Sakamoto, Takuya Kobayashi, Shogo Yamada, Daisaku Nagano, Hiroaki Tomokuni, Akira Tomimaru, Yoshito Noda, Takehiro Gotoh, Kunihito Asaoka, Tadafumi Wada, Hiroshi Kawamoto, Koichi Marubashi, Shigeru Eguchi, Hidetoshi Doki, Yuichiro Mori, Masaki PLoS One Research Article Epithelial-mesenchymal transition (EMT) is involved in the characteristics of malignancy, such as invasion, metastasis, and chemoresistance. In biliary tract cancer (BTC), EMT is induced by transforming growth factor-beta 1 (TGF-β1). The EMT is reversible; therefore, it is conceivable that it could be related to some epigenetic changes. We focused on histone deacetylase (HDAC) inhibitors as regulators of TGF-β1 signaling, and investigated their effect on EMT and chemoresistance. We employed four BTC cell lines (MzChA-1, gemcitabine-resistant MzChA-1, TFK-1, and gemcitabine-resistant TFK-1) and used vorinostat as the HDAC inhibitor. The relative mRNA expression of an epithelial marker (CDH1) and mesenchymal markers (CDH2, vimentin, SNAI1) were measured by qRT-PCR to evaluate factors associated with EMT. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed to evaluate the chemoresistance of each cell line. In addition, NOD/SCID mice were used to evaluate the effect of vorinostat in vivo. In the parent MzChA-1 and TFK-1 cell lines, TGF-β1 induced EMT and chemoresistance; while vorinostat inhibited the EMT and chemoresistance induced by TGF-β1. In gemcitabine-resistant cell lines that highly expressed TGF-β1, vorinostat inhibited EMT and attenuated chemoresistance. We showed that vorinostat inhibits nuclear translocation of SMAD4 which is a signaling factor of TGF-β1, and this is one of the mechanisms by which vorinostat regulates EMT. We also showed that vorinostat attenuates the binding affinity of SMAD4 to the CDH1-related transcription factors SNAI1, SNAI2, ZEB1, ZEB2, and TWIST. Furthermore, combination therapy with vorinostat and gemcitabine improved survival time in the mice xenografted with gemcitabine resistant MzChA-1 cells. In conclusion, vorinostat regulated TGF-β1-induced EMT and chemoresistance through inhibition of SMAD4 nuclear translocation. Public Library of Science 2016-01-04 /pmc/articles/PMC4699768/ /pubmed/26726879 http://dx.doi.org/10.1371/journal.pone.0145985 Text en © 2016 Sakamoto et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited |
spellingShingle | Research Article Sakamoto, Takuya Kobayashi, Shogo Yamada, Daisaku Nagano, Hiroaki Tomokuni, Akira Tomimaru, Yoshito Noda, Takehiro Gotoh, Kunihito Asaoka, Tadafumi Wada, Hiroshi Kawamoto, Koichi Marubashi, Shigeru Eguchi, Hidetoshi Doki, Yuichiro Mori, Masaki A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer |
title | A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer |
title_full | A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer |
title_fullStr | A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer |
title_full_unstemmed | A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer |
title_short | A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer |
title_sort | histone deacetylase inhibitor suppresses epithelial-mesenchymal transition and attenuates chemoresistance in biliary tract cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699768/ https://www.ncbi.nlm.nih.gov/pubmed/26726879 http://dx.doi.org/10.1371/journal.pone.0145985 |
work_keys_str_mv | AT sakamototakuya ahistonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT kobayashishogo ahistonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT yamadadaisaku ahistonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT naganohiroaki ahistonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT tomokuniakira ahistonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT tomimaruyoshito ahistonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT nodatakehiro ahistonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT gotohkunihito ahistonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT asaokatadafumi ahistonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT wadahiroshi ahistonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT kawamotokoichi ahistonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT marubashishigeru ahistonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT eguchihidetoshi ahistonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT dokiyuichiro ahistonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT morimasaki ahistonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT sakamototakuya histonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT kobayashishogo histonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT yamadadaisaku histonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT naganohiroaki histonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT tomokuniakira histonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT tomimaruyoshito histonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT nodatakehiro histonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT gotohkunihito histonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT asaokatadafumi histonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT wadahiroshi histonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT kawamotokoichi histonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT marubashishigeru histonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT eguchihidetoshi histonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT dokiyuichiro histonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer AT morimasaki histonedeacetylaseinhibitorsuppressesepithelialmesenchymaltransitionandattenuateschemoresistanceinbiliarytractcancer |